What You'll Learn
Table of Contents
Most Common Side Effects (GI)
Gastrointestinal effects dominate the side-effect profile of every drug in this class, by a wide margin. In order of how frequently they're reported across trials:
- 1 Nausea — the single most commonly reported side effect, especially during dose increases
- 2 Constipation — common and directly tied to slowed gastric and gut motility
- 3 Diarrhea — also common, sometimes alternating with constipation
- 4 Vomiting — less common than nausea alone, but still frequently reported
These four effects are dose-related — they tend to spike during titration (dose increases) and settle as the body adjusts to a stable dose. Not everyone experiences them, and severity varies widely across individuals in the trial data.
Less Common but Notable
This is the category where the largest, highest-quality evidence — pooled meta-analyses of tens of thousands of trial participants — becomes especially valuable, because a single trial usually isn't large enough to detect a risk increase this size reliably.
Pooling 55 placebo-controlled RCTs across type 2 diabetes, overweight/obesity, and MASLD populations, GLP-1 receptor agonists increased cholelithiasis risk (RR 1.46, 95% CI 1.09–1.97 — about 2 more cases per 1,000 patients) and probably increased GERD risk (RR 2.19, 95% CI 1.48–3.25 — about 4 more cases per 1,000). Risk was more pronounced with weight-loss-indicated use and higher doses.
View study abstract ↗An earlier, independent meta-analysis found GLP-1 receptor agonist treatment was associated with increased risk of gallbladder or biliary disease overall (RR 1.37, 95% CI 1.23–1.52), with risk rising further at higher doses, longer treatment duration, and when used specifically for weight loss rather than diabetes.
PMID: 35344001 ↗The mechanistic explanation for the gallstone signal is straightforward: rapid weight loss itself — regardless of how it's achieved — is an independent, well-established risk factor for gallstone formation, and GLP-1 therapy produces weight loss fast enough to plausibly compound that risk on top of any direct drug effect.
Hair loss
Hair shedding (telogen effluvium) is a commonly discussed concern, but the stronger explanation in the current evidence is the rapid-weight-loss trigger itself — a well-documented cause of temporary hair shedding independent of any specific weight-loss method — rather than a direct pharmacologic effect of GLP-1 receptor agonism.
Fatigue
Reduced caloric intake, possible micronutrient gaps, and reduced fluid intake are the leading plausible explanations; this isn't a headline finding in the pivotal trials so much as a commonly self-reported experience layered on top of the caloric deficit itself.
Rare but Serious: Know the Red Flags
Pancreatitis is a listed rare risk in FDA prescribing information for this drug class. Pooled trial and postmarketing surveillance data have not established a clearly and consistently elevated causal risk across the class, but it remains an actively monitored signal — severe, persistent abdominal pain (especially radiating to the back) warrants immediate medical attention, not a wait-and-see approach.
Hypoglycemia (low blood sugar) is uncommon on GLP-1 monotherapy specifically, because these drugs stimulate insulin release only when blood sugar is already elevated. Risk rises meaningfully when combined with insulin or sulfonylurea medications — a combination that requires closer glucose monitoring, set by a prescribing clinician.
Why These Side Effects Happen
Nearly every effect on this list traces back to the same core mechanism: GLP-1 receptor agonism slows gastric emptying and gut motility. That's a feature, not a bug — it's a major contributor to the appetite suppression and blood-sugar control this drug class is used for. But the same mechanism that keeps food in the stomach longer (supporting fullness) is what produces nausea, and the same slowed gut transit that reduces snacking is what produces constipation.
What Helps, According to the Evidence
| Side effect | What the mechanism-based evidence supports |
|---|---|
| Nausea | Smaller, lower-fat meals eaten more slowly; avoiding very large or greasy meals |
| Constipation | Adequate fiber and fluid intake — first-line for constipation generally, and consistent with the motility mechanism here |
| Diarrhea | Usually self-limited; hydration and electrolyte attention if it persists |
| Fatigue | Reviewing adequacy of caloric, protein, and fluid intake first |
For a full framework on eating through appetite suppression without worsening these effects, see our companion guide on protein intake and muscle preservation on GLP-1 medications.
When to Call Your Doctor
- Persistent vomiting, or any inability to keep fluids down
- Signs of dehydration (dizziness, dark urine, confusion)
- Severe or worsening abdominal pain, especially radiating to the back
- Any symptom that is getting worse over time rather than settling, or that appears alongside fever
Bottom line: Most GLP-1 side effects are common, GI, and manageable — but "common and manageable" is not the same as "ignore it." Persistent or worsening symptoms are always worth a call, not a guess.
